Patel Dinesh V Ph D - 21 Jul 2025 Form 4 Insider Report for Protagonist Therapeutics, Inc (PTGX)

Role
President and CEO, Director
Signature
/s/ Matthew Gosling, Attorney-in-Fact for Dinesh V. Patel, Ph.D.
Issuer symbol
PTGX
Transactions as of
21 Jul 2025
Transactions value $
-$2,880,044
Form type
4
Date filed
23 Jul 2025, 18:57
Previous filing
18 Jul 2025
Next filing
28 Jul 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
PATEL DINESH V PH D President and CEO, Director C/O PROTAGONIST THERAPEUTICS, INC., 7707 GATEWAY BLVD., SUITE 140, NEWARK /s/ Matthew Gosling, Attorney-in-Fact for Dinesh V. Patel, Ph.D. 2025-07-23 0001120477

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PTGX Common Stock Award $0 +25K +4.48% $0.00 583K 21 Jul 2025 Direct F1
transaction PTGX Common Stock Sale -$705K -12.9K -2.2% $54.86 571K 21 Jul 2025 Direct F2
transaction PTGX Common Stock Sale -$1.21M -22.1K -3.87% $55.05 549K 22 Jul 2025 Direct F3
transaction PTGX Common Stock Sale -$960K -17.5K -3.19% $54.79 531K 23 Jul 2025 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents settlement by the Issuer of performance stock units ("PSUs") granted to the Reporting Person under the Issuer's 2016 Equity Incentive Plan on February 26, 2021, which vested based on the Issuer's achievement of corporate performance objectives.
F2 Sale of shares to cover tax withholding obligation incurred upon settlement of PSUs.
F3 The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $55.00 to $55.19. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F4 The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $54.75 to $55.00. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.